These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31776591)

  • 21. Therapeutic antibody engineering by high efficiency cell screening.
    Doerner A; Rhiel L; Zielonka S; Kolmar H
    FEBS Lett; 2014 Jan; 588(2):278-87. PubMed ID: 24291259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant antibodies for cancer diagnosis and therapy.
    Hudson PJ; Souriau C
    Expert Opin Biol Ther; 2001 Sep; 1(5):845-55. PubMed ID: 11728219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanization of chicken monoclonal antibody using phage-display system.
    Nishibori N; Horiuchi H; Furusawa S; Matsuda H
    Mol Immunol; 2006 Feb; 43(6):634-42. PubMed ID: 16360012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribosome display for improved biotherapeutic molecules.
    Rothe A; Hosse RJ; Power BE
    Expert Opin Biol Ther; 2006 Feb; 6(2):177-87. PubMed ID: 16436043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.
    Zhao A; Tohidkia MR; Siegel DL; Coukos G; Omidi Y
    Crit Rev Biotechnol; 2016; 36(2):276-89. PubMed ID: 25394539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.
    Nagano K; Tsutsumi Y
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33504115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant Antibody Selections by Combining Phage and Yeast Display.
    Ferrara F; Soluri MF; Sblattero D
    Methods Mol Biol; 2019; 1904():339-352. PubMed ID: 30539479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammalian cell display and somatic hypermutation in vitro for human antibody discovery.
    King DJ; Bowers PM; Kehry MR; Horlick RA
    Curr Drug Discov Technol; 2014 Mar; 11(1):56-64. PubMed ID: 23978037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of human antibody gene libraries and selection of antibodies by phage display.
    Frenzel A; Kügler J; Wilke S; Schirrmann T; Hust M
    Methods Mol Biol; 2014; 1060():215-43. PubMed ID: 24037844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein and Antibody Engineering by Phage Display.
    Frei JC; Lai JR
    Methods Enzymol; 2016; 580():45-87. PubMed ID: 27586328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progression and direction of humanized antibody research].
    Lin Y; Yan XY
    Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies.
    Chan DTY; Groves MAT
    Emerg Top Life Sci; 2021 Nov; 5(5):601-608. PubMed ID: 33660765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human antibody libraries: a race to engineer and explore a larger diversity.
    Mondon P; Dubreuil O; Bouayadi K; Kharrat H
    Front Biosci; 2008 Jan; 13():1117-29. PubMed ID: 17981617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues.
    Kaleli NE; Karadag M; Kalyoncu S
    Proteins; 2019 Jul; 87(7):607-618. PubMed ID: 30883916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen.
    Okamoto T; Mukai Y; Yoshioka Y; Shibata H; Kawamura M; Yamamoto Y; Nakagawa S; Kamada H; Hayakawa T; Mayumi T; Tsutsumi Y
    Biochem Biophys Res Commun; 2004 Oct; 323(2):583-91. PubMed ID: 15369791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development trends for generation of single-chain antibody fragments.
    Farajnia S; Ahmadzadeh V; Tanomand A; Veisi K; Khosroshahi SA; Rahbarnia L
    Immunopharmacol Immunotoxicol; 2014 Oct; 36(5):297-308. PubMed ID: 25081575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.